How much funding has Avalyn raised?

Avalyn has raised $434.5M in total funding, most recently a Series D round.

Who are Avalyn's investors?

Avalyn's investors include SR One, Novo Holdings A/S, Shiv Chaudhary, Eight Roads Ventures, Suvretta Capital Management, Eventide Asset Management.

Where is Avalyn headquartered?

Avalyn is headquartered in Boston, Massachusetts, United States.

What industry is Avalyn in?

Avalyn operates in Biotech, Healthcare, Life Sciences, Therapeutics.

Avalyn

formerly Avalyn Pharmaceuticals

Avalyn Pharma Inc | Targeted therapies for rare lung diseases

Boston, United States · Founded 2011 · $434.5M raised

Headquarters: Boston, Massachusetts
Employees: 11–50
Founded: 2011
Business Model: B2B

Website: avalynpharma.com
Total Funding: $434.5M
Last Round: $100.0M Series DJul 2025
Rounds: 6

About

Avalyn is a clinical-stage biopharmaceutical company developing inhaled formulations of approved medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. By delivering drugs directly to the lungs via inhalation, Avalyn aims to improve efficacy and reduce systemic side effects compared to existing oral treatments. The company is led by CEO Lyn Baranowski and CSO Mark Surber, PhD.

Summary

Avalyn is a Biotech company based in Boston, United States, founded in 2011. It has raised $434.5M in total across 6 rounds, most recently a $100.0M Series D round in Jul 2025. Investors include SR One, Novo Holdings A/S and Shiv Chaudhary.